CA-VERIMATRIX
24.2.2020 17:42:14 CET | Business Wire | Press release
Regulatory News:
Verimatrix , (Paris:VMX) (Euronext Paris: VMX), formerly known as Inside Secure, a global provider of innovative, customer-friendly cybersecurity solutions that protect video content, endpoint devices, software and applications, today announced that Albania’s largest IPTV and OTT service provider TiBO has deployed Verimatrix Multi-DRM via the Verimatrix Secure Cloud to protect premium content that extends beyond traditional television.
Using a cloud-based Software-as-a-Service (SaaS) model, the Verimatrix Multi-DRM solution offers TiBO a convenient and cost-effective alternative to on-premise systems and operations. It is further supported by a vast range of pre-integrations with leading ecosystem partners, including Magoware, which was another key motivator for TiBO’s deployment.
“Because video content offered in Albanian language is highly sought after by pirates, it is more challenging to receive approval from studios to distribute their content in the region without a strong reputation for keeping content protected,” said Adnand Mahmuti, CEO at TiBO. “Verimatrix is able to offer us the complete package – the DRM capabilities we need, delivered via a simple and secure cloud infrastructure, underscored by its proven ability to maximize revenue for video service providers in Albania and across the world.”
Facing a high volume of illegal distribution in the region, TiBO originally enlisted Verimatrix to optimize revenue security for its OTT service, but by choosing a cloud-based security infrastructure, it was also able to unlock several added benefits. Deploying Verimatrix Multi-DRM via Verimatrix’s cloud-based infrastructure has enabled TiBO to reduce the complexity of its operations, while the SaaS business model minimizes CAPEX. Costs and complexities are further reduced by a simple HLS-only streaming format which allows content to be encoded and encrypted just once.
“This cloud-based Verimatrix Multi-DRM deployment truly checks all of the boxes for TiBO with simplicity at the core,” said Verimatrix Chief Operating Officer Asaf Ashkenazi. “Because the security framework will adapt to studio-required changes in security regime, TiBO – and the studios issuing premium content – can rest assured they will always be a step ahead of pirates.”
Verimatrix Multi-DRM offers a comprehensive, multi-screen and multi-DRM solution for premium content security and monetization with several value-add options. The deployment has laid the groundwork for TiBO to extend OTT distribution to SmartTVs, as well as tap into watermarking and analytic capabilities.
To learn more about Verimatrix Multi-DRM and how it offers a compelling choice in the busy OTT market, please visit www.verimatrix.com/solutions/multi-drm .
About TiBO
TiBO is the largest Albanian IPTV/OTT platform distributing prime video content for Albanian audiences worldwide. TiBO collaborates with the largest Content providers to offer Albanian TV shows, Movies, News, and live sport. Starting with investing simply in better connectivity TiBO has leveled up the audience's demand. The innovation brought by the OTT content solution to Albanian citizens simultaneously freed ex-pats from geographic restrictions and broadcast schedules, and fundamentally transformed the way video is consumed.
With Global ecosystem leaders on the side, TiBO continuously invests in new technologies that improve and secure content distribution. TiBO is highly engaged to protect the content by delivering qualitative and secured entertainment in all playout devices for big and small screens (STB-s, Smart TV-s; Mobiles and tablets). For the end-user, it’s all fairly seamless and indistinguishable but beneath the technology, there is a range of business models that inevitably bring to another level not only the television experience but the entire industry. What TiBO has ignited already is an irreversible shift to content distribution via OTT which pushes further than ever the boundaries, to enable new types of applications and services across the industry.
To find out more about TiBO IPTV/OTT distribution Platform visit www.tibo.tv or follow in social media, Twitter , Facebook , LinkedIn , Instagram .
About Verimatrix
Verimatrix (Euronext Paris: VMX), formerly known as Inside Secure, is a trusted business partner providing software security and business intelligence solutions that protect content, applications, and devices across multiple markets. Many of the world’s largest service providers and leading innovators trust Verimatrix to protect systems that people depend on every day. With more than 20 years of experience and the top minds in the industry, the company is uniquely positioned to understand and proactively anticipate security and business challenges for customers. Verimatrix partners provide innovative, customer-friendly solutions that are cost-effective, easy to deploy and supported with responsive customer service teams based worldwide. To learn more, visit www.verimatrix.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200224005579/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom